NXL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nexalin Technology Inc (NXL) is not a strong buy at this moment for a beginner investor with a long-term strategy. While insider buying and the company's innovative clinical trials for drug-free insomnia treatment are positive catalysts, the company's weak financial performance and lack of significant trading trends or proprietary trading signals suggest caution. The stock may be worth monitoring for future developments, but it is not an immediate buy.
The MACD histogram is positive and expanding (0.014), indicating a bullish signal. RSI is neutral at 54.935, and moving averages are converging, showing no strong directional trend. Key support is at 0.39, and resistance is at 0.606.
Insider buying has increased by 117.11% over the last month. Nexalin is initiating a pivotal clinical trial for its HALO Clarity program, targeting FDA approval for a drug-free insomnia treatment, which could address a significant market need.
The company's financial performance in 2025/Q3 showed a significant revenue drop (-49.63% YoY), a net income decline (-7.02% YoY), and a sharp EPS decrease (-43.48% YoY). These factors indicate weak financial health.
In 2025/Q3, revenue dropped to 18,149 (-49.63% YoY), net income fell to -2,276,311 (-7.02% YoY), and EPS declined to -0.13 (-43.48% YoY). However, gross margin improved to 78.25% (+20.81% YoY).
No data available for analyst ratings or price target changes.
